Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding another nail to the coffin of niacin therapy for heart patients.
Merck has already given up on the drug that combines extended-release niacin with an experimental agent called laropiprant, designed to prevent the uncomfortable facial flushing associated with niacin.
Serious side effects seen with failed Merck niacin drug
Few insurers now cover services required in 2014 under health care law
Just 2 percent of health plans available to consumers in the private insurance market offer all the coverage that will become mandatory next year under the health care overhaul, a new analysis has found.
That means that only about one in 50 plans are now in compliance with the main requirements of the Patient Protection and Affordable Care Act, according to HealthPocket Inc., a Sunnyvale, Calif., technology firm that “compares and ranks” health plans.
Popular tuna brands recalled for improperly sealed can
If you have stocked up on canned tuna in the past couple of months, check your cupboards: Some cans of Bumble Bee and Chicken of the Sea tuna have been recalled because the cans were improperly sealed, manufacturers say.
No illnesses have been reported, the companies say. But "loose seals or seams could result in product contamination by spoilage organisms or pathogens and lead to illness if consumed," according to a statement from Bumble Bee Foods posted by the Food and Drug Administration. Tri-Union Seafoods, which makes Chicken of the Sea, released a nearly identical statement.
Behind rosy survival claims of Cancer Treatment Centers of America
When the local doctor who had been treating Vicky Hilborn told her that her rare cancer had spread throughout her body, including her brain, she and her husband refused to accept a death sentence. Within days, Keith Hilborn was on the phone with an "oncology information specialist" at Cancer Treatment Centers of America.
Hilborn had seen CTCA's website touting survival rates better than national averages. His call secured Vicky an appointment at the for-profit, privately held company's Philadelphia affiliate, Eastern Regional Medical Center. There, the oncologist who examined Vicky told the couple he had treated other cases of histiocytic sarcoma, the cancer of immune-system cells that she had.
CDC says ‘nightmare bacteria’ a growing threat
Federal officials warned Tuesday that “nightmare bacteria” — including the deadly superbug that struck a National Institutes of Health facility two years ago — are increasingly resistant to even the strongest antibiotics, posing a growing threat to hospitals and nursing homes nationwide.
Thomas Frieden, director of the Centers for Disease Control and Prevention, said at a news conference: “It’s not often that our scientists come to me and say we have a very serious problem and we need to sound an alarm. But that’s exactly what we are doing today.”
Activists fight FDA approval of AquaBounty’s genetically engineered salmon
Every summer since 1979, Kim Hubert has fished for sockeye salmon in Alaska’s Bristol Bay. It’s a family business in tiny Togiak that has, from time to time, also employed his wife and three children.
Hubert and his 21-year-old daughter work the nets now. They’re small permit holders who may catch and sell thousands of salmon in their nets each year, depending on the success of the run.
Bayer to challenge India generic cancer drug ruling
German drug maker Bayer has said it will challenge India's decision to allow the production of a cheaper generic copy of a patented cancer drug.
Last year, India allowed Natco Pharma to produce Nexavar and, on Monday, the patent appeals office rejected Bayer's plea to overturn that ruling. On Tuesday, Bayer said it "strongly" disagreed with the decision and would appeal in the high court of Mumbai.
Bayer sells the drug for 280,000 rupees ($5,118; £3,374) for a 120-tablet pack.
More Articles...
Page 9 of 193
Health Glance





























